

# CONTENTS

---

Preface .....	v
Contributors .....	ix
1 Signal Transduction Pathways: A Goldmine for Therapeutic Targets .....	1
Paul Workman	
2 The Biochemistry of Farnesyltransferase and Geranylgeranyltransferase I .....	21
Chih-Chin Huang, Carol A. Fierke, and Patrick J. Casey	
3 Structures of Protein Farnesyltransferase .....	37
Stephen B. Long and Lorena S. Beese	
4 Peptidomimetic-Based Inhibitors of Farnesyltransferase .....	49
David Knowles, Jiazhi Sun, Saul Rosenberg, Saïd M. Sebti, and Andrew D. Hamilton	
5 Antitumor Efficacy of a Farnesyltransferase Inhibitor in Transgenic Mice .....	65
Jackson B. Gibbs, Samuel L. Graham, George D. Hartman, Kenneth S. Koblan, Nancy E. Kohl, Charles Omer, Angel Pellicier, Jolene Windle, and Allen Oliff	
6 Development of Farnesyltransferase Inhibitors as Potential Antitumor Agents .....	71
Veeraswamy Manne, Frank Lee, Ning Yan, Craig Fairchild, and William C. Rose	
7 Tricyclic Farnesyl Protein Transferase Inhibitors: Antitumor Activity and Effects on Protein Prenylation .....	87
W. Robert Bishop, James J.-K. Pai, Lydia Armstrong, Marguerite B. Dalton, Ronald J. Doll, Arthur Taveras, George Njoroge, Michael Sinensky, Fang Zhang, Ming Liu, and Paul Kirschmeier	
8 Histidylbenzylglycinamides: A Novel Class of Farnesyl Diphosphate- Competitive Peptidic Farnesyltransferase Inhibitors .....	103
Judith S. Sebolt-Leopold, Daniele M. Leonard, and W. R. Leopold	
9 From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase .....	115
Patrick Mailliet, Abdel Laoui, Jean-Dominique Bourzat, Marc Capet, Michel Chevé, Alain Commerçon, Norbert Dereu, Alain LeBrun, Jean-Paul Martin, Jean-François Peyronel, Christophe Salagnad, Fabienne Thompson, Martine Zucco, Jean-Dominique Guitton, Guy Pantel, Marie-Christine Bissery, Clive Brealey, Jacques Lavayre, Yves Lelièvre, Jean-François Riou, Patricia Vrignaud, Marc Duchesne, and François Lavelle	

10	Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors .....	145
	Fuyuhiko Tamanoi, Keith Del Villar, Nicole Robinson, MeeRhan Kim, Jun Urano, and Wenli Yang	
11	Effects of Farnesyltransferase Inhibitors on Cytoskeleton, Cell Transformation, and Tumorigenesis: The FTI-Rho Hypothesis .....	159
	George C. Prendergast	
12	Prenyltransferase Inhibitors as Radiosensitizers .....	171
	Eric J. Bernhard, Ruth J. Muschel, Elizabeth Cohen-Jonathan, Gilles Favre, Andrew D. Hamilton, Saïd M. Sebti, and W. Gillies McKenna	
13	Farnesyltransferase and Geranylgeranyltransferase I Inhibitors as Novel Agents for Cancer and Cardiovascular Diseases .....	197
	Saïd M. Sebti and Andrew D. Hamilton	
14	Protein Prenylation in Trypanosomatids: A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases .....	221
	Michael H. Gelb, Frederick S. Buckner, Kohei Yokoyama, Junko Ohkanda, Andrew D. Hamilton, Lisa Nguyen, Bartira Rossi-Bergmann, Kenneth D. Stuart, Saïd M. Sebti, and Wesley C. Van Voorhis	
15	Early Clinical Experience with Farnesyl Protein Transferase Inhibitors: From the Bench to the Bedside .....	233
	Amita Patnaik and Eric K. Rowinsky	
16	Phase I Trial of Oral R115777 in Patients with Refractory Solid Tumors: Preliminary Results .....	251
	Gary R. Hudes and Jessie Schol	
17	Farnesyltransferase and Geranylgeranyltransferase Inhibitors: The Saga Continues .....	255
	Adrienne D. Cox, L. Gerard Toussaint III, James J. Fiordalisi, Kelley Rogers-Graham, and Channing J. Der	
	Index .....	275



<http://www.springer.com/978-0-89603-629-1>

Farnesyltransferase Inhibitors in Cancer Therapy

Sebti, S.M.; Hamilton, A.D. (Eds.)

2001, XII, 280 p., Hardcover

ISBN: 978-0-89603-629-1

A product of Humana Press